It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Myasthenia gravis (MG) should be classified according ... atrophy), age at debut (< or >50 years), symptom localization (generalized, ocular) and severity. With optimal treatment, the prognosis ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of ...

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

This is a monoclonal antibody that is targeting three indications: generalized myasthenia gravis of gMG, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.